(Delayed) Quarterly Update_Q2 FY2026
Filed with TSE · · 21 pages · English
None of the securities of Innovacell Inc. (the "Company") have been or will be registered under the United States Securities Act of 1933, as amended, and no offering or sale of any of the Company’s securities may be made in the United States absent registration or an applicable exemption from registration. This document has been prepared solely for the purpose of providing information related to t
Earlier from Innovacell
- Patient Enrollment Status of the ICEF15 Multi-Regional Phase III Clinical Trial (Fidelia) and Completion of Patient Recruitment in Japan and Europe
- Announcement Regarding the Execution of a Product Commercialization Agreement with EVERSANA Life Science Services, LLC for the U.S. Market
- Announcement Regarding Completion of FDA IND Review and Approval to Include U.S. Sites and Patients in the ICEF15 Multi-Regional Phase III Trial
Follow Innovacell into a list and get an email when it puts out news.
Follow Innovacell